摘要:
Cyclic urea derivatives having the general formula (I), in which R1 to R9, Ra, Rb, A, D, E and F have the definitions given in the first claim, their tautomers, their stereoisomers, including their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids or bases, have valuable pharmacological and other properties, preferably aggregation-inhibiting effects. Also disclosed are medicaments containing said compounds, their use and a process for producing the same.
摘要:
Disclosed are five-membered heterocycles of general formula (I) in which X1-X5 have the meanings indicated in claim 1, the tautomers and stereoisomers thereof including mixtures thereof, and the salts thereof especially those salts with physiologically acceptable acids and bases with valuable pharmacological properties, preferably aggregation-inhibiting properties. Also disclosed are pharmaceutical agents containing these compounds and the use of the compounds as well as methods of producing them.
摘要:
Piperazine derivatives have the general formula (I), in which Ra, Y1 to Y3 and E have the definitions given in the first claim. Also disclosed are their tautomers, their stereoisomers, including their mixtures and their salts, in particular their physiologically tolerable salts with inorganic or organic acids or bases, having valuable pharmacological properties, preferably aggregation-inhibiting effects, medicaments containing these compounds, their use and a process for preparing the same.
摘要:
The invention concerns carboxylic acid derivatives of the general formula (I), in which Ra to Rc, A, B, D, E and X1 to X3 are as defined in claim 1, their stereoisomers, including mixtures and salts, in particular physiologically tolerated salts, with inorganic or organic acids or bases, which exhibit useful pharmacological properties, preferably an aggregation-inhibiting action. The invention also concerns drugs containing such compounds, their use and methods of preparing them.
摘要:
The present invention relates to phenyl amidines of general formula (I), in which R1 to R5 are as defined in claim 1, their tautomers, their stereoisomers and their mixtures and their salts, especially their physiologically acceptable salts with inorganic or organic acids or bases also having valuable pharmacological properties, preferably aggregation-limiting effects. The invention also relates to medicaments containing these compounds, their use and a process for producing them.